文献速递前列腺癌

局部晚期与转移性激素敏感性前列腺癌的联合治疗

Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer.
PubMed 文献 · Eur Urol · 2025-02-12

本叙述性协作综述检索截至2024年11月的文献,总结局部晚期与转移性激素敏感性前列腺癌(mHSPC)联合治疗的证据。ADT联合ARPI的双药方案现被视为mHSPC的标准治疗,特定亚组可考虑加用多西他赛的三药方案;早期强化可改善特定亚组生存,但可能伴长期毒性。

要点

  • ADT联合ARPI的双药方案现被视为mHSPC的标准治疗。
  • 特定亚组可考虑在双药基础上加用多西他赛的三药方案。
  • 早期联合强化可改善特定亚组生存,但可能伴长期毒性。

核心结论

  • 在特定亚组中,早期联合治疗强化可改善生存,但可能伴长期毒性。

研究设计与样本

  • 叙述性协作综述,文献检索截至2024年11月,检索词包括「转移性激素敏感性前列腺癌」「转移性去势敏感性前列腺癌」「局部晚期前列腺癌」「联合」「强化」「降阶梯」,由作者根据科学价值、临床影响和相关性选择文献。

主要发现

  • 以雄激素剥夺治疗(ADT)为骨架联合雄激素受体通路抑制剂(ARPI)的双药方案现被视为mHSPC的标准治疗。
  • 在特定亚组中可考虑纳入多西他赛的三药方案。
  • 针对高危局限性和局部晚期疾病,已有若干试验评估在标准手术或放疗联合ADT基础上加用联合治疗的获益。
  • 生存的持续改善使焦点转向优化患者选择以进行治疗强化,某些情况下进行降阶梯,目标是减少不必要的过度治疗并尽量减少长期治疗毒性。
  • 前列腺特异性膜抗原正电子发射断层扫描的整合可导致转移性疾病更早被检出,使患者选择尤为重要。

关键数值与推荐

  • ADT联合ARPI的双药方案现被视为mHSPC的标准治疗。
  • 在特定亚组中可考虑加用多西他赛的三药方案。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本文为叙述性协作综述,文献由作者根据科学价值、临床影响和相关性选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The treatment landscape for advanced prostate cancer has evolved significantly over the past decade. The introduction of docetaxel, androgen receptor pathway inhibitors (ARPIs), poly(ADP-ribose) polymerase inhibitors, and targeted radionuclides has redefined the treatment paradigm, with a focus now on early treatment intensification through combination therapies. This narrative collaborative review summarises the current evidence of combination therapies in locally advanced and metastatic hormone-sensitive prostate cancer (mHSPC). METHODS: We conducted a literature search up to November 2024. Search terms included "metastatic hormone-sensitive prostate cancer", "metastatic castration-sensitive prostate cancer", "locally advanced prostate cancer", "combination", "intensification", and "de-escalation". Articles were selected by the authors based on their scientific merit, clinical impact, and relevance to provide a summary of the evidence surrounding combination therapy in locally advanced prostate cancer and mHSPC. KEY FINDINGS AND LIMITATIONS: A doublet approach with an androgen deprivation therapy (ADT) backbone and an ARPI is now considered the standard treatment for mHSPC, with a triplet regimen incorporating docetaxel considered in select subgroups. Similar efforts to improve survival in the high-risk localised and locally advanced disease setting have led to several trials evaluating the benefit of combination therapy in addition to standard-of-care surgery or radiotherapy with ADT. Continued improvements in survival have turned the focus to optimising patient selection for treatment intensification and, in some cases, de-escalation, with the goal of reducing unnecessary overtreatment and minimising harm from long-term treatment toxicity. This is particularly important with the integration of prostate-specific membrane antigen positron emission tomography, which has led to the earlier detection of metastatic disease. CONCLUSIONS AND CLINICAL IMPLICATIONS: In select subgroups, early treatment intensification with combination therapy leads to improved survival, though it can be associated with long-term toxicity.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Azad AA, Kostos L, Agarwal N, et al. Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer. Eur Urol. 2025. PMID: 39947976. doi:10.1016/j.eururo.2025.01.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。